Cedric Hermans and Glenn Pierce On The Essential Role of A Positive Reinvestment Cycle in Hemophilia
Cedric Hermans, Head of Haemophilia Centre at the Cliniques Universitaires Saint-Luc in Brussels, shared on LinkedIn:
”Hemophilia stands out among rare diseases for its remarkable therapeutic progress, a success built on decades of innovation, scientific discovery, and investment.
From the cloning of FVIII and FIX genes to the arrival of gene therapy, each milestone has transformed lives.
Global advocacy by WFH, EAHAD, and NBDF has been key to ensuring access and safety.
Yet, sustaining this progress requires continued commitment and investment, so that every person with hemophilia can benefit from the full promise of science.”
Read the full article here.
Article: Therapeutic innovations in hemophilia: the essential role of a positive reinvestment cycle
Authors: Cedric Hermans, Glenn F Pierce
Stay updated on all scientific advances in the field of hemophilia with Hemostasis Today.
-
May 6, 2026, 02:58Limiaa Babikir: What Is Polyspecific DAT?
-
May 6, 2026, 02:47Karen Rollinson: Grateful to Be Connecting with so Many Families and Advocates at HFA 2026 in New Orleans
-
May 6, 2026, 02:38Moustafa Abdou: Is the Bone Marrow Examination Still the ‘Gold Standard’?
-
May 6, 2026, 02:23Khaled Musallam: When the Worlds of Thalassemia and Hemophilia Converge
-
May 6, 2026, 02:12Caitlin Raymond: How STOP-BABESIOSIS Just Rewrote 40 Years of Practice
-
May 5, 2026, 16:28Nikolay Novitski: A New Era in Cardiovascular Prevention
-
May 5, 2026, 16:23Satyam Arora: Best Abstract Award in Pediatric Apheresis at ASFA 2026 Congress
-
May 5, 2026, 16:17Hannah Omunakwe: Your Sick Child Has a Clot. Did You See That Coming?
-
May 5, 2026, 15:57Venous Thromboembolism Risk in Pregnancy and the Postpartum Period – NBCA